176 related articles for article (PubMed ID: 20690804)
1. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
[TBL] [Abstract][Full Text] [Related]
2. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
5. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
[TBL] [Abstract][Full Text] [Related]
6. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
Geradts J; Bean SM; Bentley RC; Barry WT
Cancer Invest; 2010 Nov; 28(9):969-77. PubMed ID: 20873988
[TBL] [Abstract][Full Text] [Related]
7. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
8. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
Wolf I; Ben-Baruch N; Shapira-Frommer R; Rizel S; Goldberg H; Yaal-Hahoshen N; Klein B; Geffen DB; Kaufman B
Cancer; 2008 Feb; 112(4):731-6. PubMed ID: 18076012
[TBL] [Abstract][Full Text] [Related]
9. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
10. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
11. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
Lee JJ; Shen J
Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
14. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
15. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
16. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
17. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
